Nasdaq Sends Delisting Notice to Actuate Therapeutics Over Market Value Shortfall
ACTU sits 24% above its 52-week low of $1.16.
Summary
Actuate Therapeutics received a Nasdaq delisting notice after its market value fell below the $50 million minimum. The company has until January 11, 2027 to regain compliance, but its precarious cash position and going concern warning make this a critical challenge.
Key Events · Legal and Risk Events · ACTU
-
Nasdaq Delisting Notice Received
On July 15, 2026, the company received notice that its Market Value of Listed Securities (MVLS) fell below the $50 million minimum required for continued listing on the Nasdaq Global Market.
-
180-Day Compliance Window
To regain compliance, the company must maintain an MVLS of at least $50 million for ten consecutive business days by January 11, 2027.
-
Going Concern Overlap
The delisting notice compounds existing liquidity pressures; the last 10-Q warned that cash would only fund operations through July 2026, raising doubts about the ability to sustain a $50 million market value.
-
Potential Fallback to Nasdaq Capital Market
If compliance is not regained, the company may apply to transfer to the Nasdaq Capital Market, though success is not assured and delisting remains a risk.
Analysis · ACTU · Life Sciences
A delisting risk has emerged after Nasdaq notified Actuate Therapeutics that its market value of listed securities slipped below the $50 million minimum. The company now has 180 days, until January 11, 2027, to regain compliance by sustaining a market value above $50 million for ten consecutive business days. Already facing a going concern warning with cash only through July 2026, the path to compliance looks uncertain. Failure could force a move to the Nasdaq Capital Market or outright delisting, which would severely impact liquidity and investor confidence.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.7% of the 383 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACTU was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.5M. The 52-week trading range was $1.16 to $9.22. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.